Clinical-stage biotechnology company Allogene Therapeutics and start-up company Overland Pharmaceuticals are forming a new joint company named Allogene Overland Biopharm, a separate venture that will develop, manufacture and commercialize allogeneic CAR T (AlloCAR T™) therapies for patients with cancer in greater China, Taiwan, South Korea and Singapore.

Westlake Village BioPartners launched two new funds totaling $500 million that will be used to build and invest in promising life sciences companies, with a particular focus on bolstering companies in the Los Angeles area.

Regeneron Pharmaceuticals reported that it is pausing enrollment in two of its clinical trials for odronextamab for lymphoma. The U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the trials, requesting Regeneron modify protocols to decrease the occurrence of cytokine release syndrome in patients.

North Carolina-based vTv Therapeutics has provided worldwide rights for its novel clinical-stage Nrf2 activator compound, HPP971, to newly formed Anteris Bio, a biotech investment firm that will further develop HPP971 as a new treatment for renal disease.

Amgen’s osteoporosis drug denosumab is approved as Xgeva for the prevention and treatment of some bone metastases in cancer. But could the drug’s mechanism of action help breast cancer patients respond to immunotherapy drugs that typically don’t work well in those tumors?

When gene therapy developer Generation Bio raised $110 million in venture funding in January and then followed up six months later with a $230 million initial public offering, it was as sure a sign as any that investors are stoked about the next generation of gene therapies to treat rare diseases.

The FDA has told Regeneron to hit the brakes on its experimental blood cancer drug trial over safety concerns.

Digital pathology developer Paige has received two European approvals for its artificial-intelligence-powered diagnostic platforms in breast and prostate cancers.

Acutus Medical has received two CE marks this week for heart treatment devices and access tools and has begun their European commercial launch.

Most approaches to preventing heart attacks focus on ameliorating risk factors like high cholesterol or high blood pressure. But what if heart attacks could be prevented altogether by targeting genes that raise the risk of coronary artery disease?